ezm0414
·Code: EZM0414
ezm0414: developed by 1 company · 1 clinical trial tracked.
ezm0414 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ezm0414 to EPZM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ezm0414 → EPZM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Multiple Myeloma, RefractoryDiffuse Large B-Cell Lymphoma
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Epizyme, Inc. (EPZM) Multiple Myeloma, Refractory | Phase 1 |
Clinical Trials (1)
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Primary endpoint: Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Interventionalopen13 targetStarted 2022-05Completion 2024-048 sites · United StatesEpizyme, Inc.
Frequently asked questions
Who is developing ezm0414?
ezm0414 is being developed by Epizyme, Inc..
How many clinical trials involve ezm0414?
BioSniper tracks 1 clinical trial involving ezm0414.